-
Posts
38426 -
Joined
-
Days Won
2
Content Type
Profiles
Forums
Store
Downloads
Recruiting - 2020
2019-2020 Football Season
Football
Entertainment
Sports
News and Business
Cloak Room
Transfer Portal
Recruiting
Events
Everything posted by TwiceHorn
-
CEO of UHG Shot and Killed in NYC - WTF is wrong with you New York
TwiceHorn replied to Bevo's topic in Daily Texan
I don't work for pharma, that's not my area. I am, however, a patent lawyer. -
Fuck. Your. Own. Face.
-
CEO of UHG Shot and Killed in NYC - WTF is wrong with you New York
TwiceHorn replied to Bevo's topic in Daily Texan
More to the point, the major complaint about patents is extension of a patent monopoly beyond the initial 20-years-from-filing term. Since the 1995 changes to the patent laws, that has become less of an issue, because all patents in a family of related patents expire on the same day. The other major complaint seems to be "broadening" the monopoly beyond the basic drug composition. Yes, pharma files a shitload of patents, often on things beyond or peripheral to the original composition and dosage and method of manufacturing, creating an alleged "patent thickpolet." But the reality is that the thicket boils down to a few basic patents and the broadened monopoly is more a theoretical construct and not a real impediment. The rest of the problems, and I'd submit the bigger problems are external to the patent system or very specific to drug-related patent legislation, that maybe should be repealed or refined. For example, in that I-Mak paper you cited, one of the more alarming stats is that Enbrel seems to go off-patent in the US in 2029 versus 2016 in the EU. What happened there is Amgen's predecessor licensed the composition from UT and applied for a series of patents on top of UTs that expired in 2016. It was one of the first biologics invented and approved for a therapeutic use. But where things went different is that Roche applied for a patent on manufacturing such drugs that proved to be hugely important to the industry. Amgen bought that technology and patent family, extending the monopoly, not on Enbrel, but on the method of manufacturing TNF inhibitors and similar drugs that seems to be indispensable to the technology. That set of patents expires in 2029 in the US, through a quirk relating to the 1995 patent law changes. Europe, on the other hand, has always had 20-year-from-filing terms, so the Roche/Amgen patents expired at approximately the same time. So, like shit software patents filed in the 80s and early 90s that fueled the "troll problem." it will take some time for pre-1995 patents to shake out of the system so that everything expires at the same time. Like the "troll problem," there are some anomalies in the system that will work themselves out and probably shouldn't be "reacted to" at this late date. -
CEO of UHG Shot and Killed in NYC - WTF is wrong with you New York
TwiceHorn replied to Bevo's topic in Daily Texan
I never said any of that. I find the patent analyses of outfits like I-Mak to be rather facile, however. The patent system as applied to pharma has some peculiarities that are not generic to the patent system as a whole. Some are specific to drugs, as in patent term extensions and the treatment of generics under Hatch-Waxman. Other problems are more directly tied to the FDA, which grants exclusivity by name and de facto in ways unrelated to the patent system. Any efforts at patent reform aimed at restraining pharma need to carefully do just that, so as not to fuck it up for the other thousands of users of the patent system. But with interested parties whipping up uninformed outrage, I'm not confident that's going to happen. Also, note that the proposed solutions above are mostly all outside of the patent system. -
CEO of UHG Shot and Killed in NYC - WTF is wrong with you New York
TwiceHorn replied to Bevo's topic in Daily Texan
Well, that's not usually the reality. It is true that pharma milks the living shit out of the patent system and every other legal/regulatory regime applicable to them. But, in almost every patent thicket, it boils down to a relatively small handful of patents that have competitive value, and those tend to be focused on the actual technological merit of the invention, rather than some peripheral, possibly trivial bullshit. If you drill down on any of the alleged patent thickets, you'll find that there are usually fewer than 10 patents, in one country, at least, that are enforcing the monopoly. And, expiration dates matter. Tremendously. It doesn't matter how many patents cover something if they all expire on the same day: they're off-patent on that day. And, generic manufacturers aren't helpless. They're as sophisticated as the "innovators," but lack the leg up that innovation confers. They are frequently in pari delicto with the innovators in taking ANDA infringement settlements that pay them to hold off pursuing valid claims until patent expiration or some other event. In many cases, a "generic" on one drug will be "brand" or innovator on another. -
Bill Norton is such an ordinary, white bread name these days, it almost seems like it's made up.
-
One thing that's wrong with her, she ain't got no tittays.
-
CEO of UHG Shot and Killed in NYC - WTF is wrong with you New York
TwiceHorn replied to Bevo's topic in Daily Texan
Shkreli didn't even deal in patented drugs. His gambit was "orphan drugs." https://en.wikipedia.org/wiki/Orphan_drug The key passage there is this: Under the ODA orphan drug sponsors qualify for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), "tax credits of up to 50% of R&D costs, R&D grants, waived FDA fees, protocol assistance[10]: 660 and may get clinical trial tax incentives.[13] -
CEO of UHG Shot and Killed in NYC - WTF is wrong with you New York
TwiceHorn replied to Bevo's topic in Daily Texan
Just for the record, it is not the combination of any old syringe with the pharmaceutical composition that makes it patentable. The syringes have special features that are unique to the composition in question, or to the type of patient or some such. It's really just a patent on an insulin syringe or applicator. And infringement is easily avoided by selling the composition/drug in a vial, as you note. But there are some strange things going on in pharma where it seems only single-use syringes get prescribed and the vial gets left out. It is interesting to know that the analogs are an actual improvement on straight insulin. I should say very interesting in that it has improved your outcome. In the patent game more broadly, there are patented improvements that aren't really improvements, but various anomalies give them the market reception of a massive improvement. I'm not actually aware of many of those in blockbuster or important drugs, other than the syringe-type scenario, which I guess is like prescribing the branded over the generic, but dialed to 11. -
CEO of UHG Shot and Killed in NYC - WTF is wrong with you New York
TwiceHorn replied to Bevo's topic in Daily Texan
Of course I'm aware of patent thickets, I do this for a living. The patents in a thicket all expire on the same day One of the main things driving the US problem with generics is that filing an ANDA is considered an act of infringement, so a potential generic doesn't have to be made, used or sold in the US (the usual acts of infringement) before a patent owner can sue. Otherwise, a generic manufacturer could be approved and ready to sell on patent expiration, but not here. That's not applicable to any other kind of patent. It's the result of pharma lobbying. -
CEO of UHG Shot and Killed in NYC - WTF is wrong with you New York
TwiceHorn replied to Bevo's topic in Daily Texan
That's not the basis for a patent term extension. https://www.law.cornell.edu/uscode/text/35/156 Such extensions are based on the length of the regulatory review period. The "illusory improvement" game was effectively ended in 1996. -
CEO of UHG Shot and Killed in NYC - WTF is wrong with you New York
TwiceHorn replied to Bevo's topic in Daily Texan
I should add that's "earliest filing date." So, you file a patent on the basic composition, then you add dosages, then you maybe add on some adjuvants or time-release compounds, or whatever. All of those patents are going to expire on the same day, subject to patent term extensions. Before 1995, those add-on patents would all be separate patents, with separate, later grant dates and a term running 17 years from that grant date. There were some ways to keep the old law applicable to post 1996 filings, but those ran out after a couple of years. -
Well, here's the thing on that. Brain chemistry that isn't quite right is every bit as physical as a pancreas that doesn't work right, or some cells that start to mutate and divide into cancer. Sure, it's not a broken leg or skull, but there are lots of diseases that involve a malfunctioning body part with no external cause. So, with the stigma, you're part of the way there, but there's no valid reason to even apply "mental" to the illness.
-
CEO of UHG Shot and Killed in NYC - WTF is wrong with you New York
TwiceHorn replied to Bevo's topic in Daily Texan
Those days are pretty much over. In 1995, we amended the patent laws so that most or all related applications expire at the same time, 20 years from their filing date. Patents are also published at 18 months after filing, so earlier-filed patents become prior art against later filed. Patent term extensions are available when drugs experience delays in approval. And FDA grants seven years of exclusivity upon approval, patents notwithstanding. But, for the most part, drug patents expire 20 years from filing. The other trick that is au courant is to package in some kind of single dose syringe or other package that is patented and for some dumb reason the drug in a vial never gets prescribed anymore. -
Fucking drug cartel bosses get assasinated pretty routinely, or arrested or otherwise taken off the board. Doesn't change a gotdamn thing. Demand side is the answer.
-
Joe Biden 2024 thread - Dark Brandon Where Art Thou?
TwiceHorn replied to StassneyHorn's topic in Cloak Room
Don't think so. Carter did issue a blanket pardon by presidential proclamation and an associated Executive Order telling the AG to terminate all prosecutions and investigations of violations of the Military Selective Service Act. https://www.justice.gov/pardon/proclamation-4483-granting-pardon-violations-selective-service-act I think the latter was more effective than the former, legally. Also, I suspect that limitations had expired on the vast majority of cases that hadn't been indicated by 1977. As far as immigration goes, it is a civil proceeding and a criminal conviction of anything (including illegal entry) is not necessary for deportation. So that was Trump's effort to popularize the whole thing, by variously calling them all criminals, or promising to deport only those convicted of crimes. -
HBO owned Cinemax from jump. But I think the answer is that the HBO streaming service contains a bit more content than HBO did, to include the "second tier" content of Cinemax. Also, I suppose "max" tested out better when they went from HBO.com to HBOMax to Max. However, I recently learned that Cinemax is back as a provider-only streaming service offering different content from HBO. Also reading that WB wants to sort of reserve the HBO name as like an old-school studio, producing original programming.
-
Youth Minister's (and other pervs) Thread of Shame
TwiceHorn replied to tx 3 putt's topic in Daily Texan
So, what are you trying to do here? There's 24 pages of posts here, almost none of them involving LGBTQ. Somewhere between about 8 and 15% of the US population identifies as LGBTQ. So it would be expected that a few of the wackjobs would be LGBTQ. But you know who is seriously overrepresented on this thread? Not teh gheys, but the congregational "Christians" that often as not are wholly supportive of the oppression of LGBTQ. -
Probably accurate. But doesn't perhaps account or the addition of jobs.
-
*trademark
-
CEO of UHG Shot and Killed in NYC - WTF is wrong with you New York
TwiceHorn replied to Bevo's topic in Daily Texan
I can't cite any sources, but yeah, that's my sense. University research provides basic ideas, that usually need to be refined into something commercially practicable and manufactured. -
I'm talking about founders because that's what Hermanator said.
Football ... Basketball ... Baseball ... Other Sports ... Futbol ... 🤫995🤫 ... Gambling ... Movies & TV ... Music ... Hobbies ... Lulz ... Food & Travel ... Daily Texan ... Business and Markets ... Cloak Room ... Help ... For Sale ... Board Discussion ... Subscribe!... Donate!... Advertise... COOKIE MONSTER!